Both GLP-1 receptor agonists and SGLT2 inhibitors linked to reduced risk for ADRD, with no significant difference between them.

Lori Berard, RN, DCE, Diabetes Educator, Nurse Consultant, reviews SGLT2's mechanism of action and benefits and discusses how ...

Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 ...

Ellen Behrend, VMD, PhD, MS, DACVIM (SAIM): As far as side effects, the most common are gastrointestinal. And right now there ...

Feline diabetes mellitus (DM) is currently understood to have strong similarities to human type 2 diabetes. Veterinarians have traditionally relied upon insulin therapy to treat feline DM. However, ...

In patients with heart failure, SGLT2 inhibitors after TAVI are associated with major risk reductions in a clinical trial that multiple experts are calling practice changing.

The analysis supports the integration of sodium-glucose cotransporter 2 (SGLT2) inhibitors into treatment paradigms for ...

Patients with low skeletal muscle mass are at a higher risk of falling. Certain diabetes medications, particularly SGLT2 ...

A major new study finds that certain diabetes medications, including GLP-1 and SGLT2 inhibitors, may be linked to a reduced ...

Adding Farxiga (dapagliflozin) to standard care significantly reduced the risk of death or worsening heart failure in older ...

Dozens of trials testing GLP-1 drugs like semaglutide, the medicine in Ozempic and Wegovy, against a placebo suggest that ...